Novartis Licenses Spark’s Retinal Gene Therapy Outside US in $170 Million Deal

January 26, 2018: By Jon Swedien

Voretigene neparvovec

Novartis will develop and commercialize Spark Therapeutics’ gene therapy, voretigene neparvovec, outside the US under a licensing deal potentially worth more than $170 million, Spark announced Jan. 24.

Philadelphia-based Spark will continue to commercialize the gene therapy in the US under the brand name Luxturna.

Novartis, of Basel, Switzerland, will pay Spark $105 million in cash up front, and Spark is eligible to receive up to an additional $65 million in cash milestone payments and a royalty on net sales outside the US, Spark said.

The additional payments will be based on near-term European regulatory approval and initial sales outside the US in certain markets, the companies said.

Spark will retain regulatory responsibility for obtaining European Medicines Agency approval for the gene therapy. Spark also entered into a separate agreement to manufacture and supply investigational voretigene neparvovec to Novartis, the companies said.

On Dec. 19, the US FDA approved Luxturna for the treatment of retinal dystrophies caused by mutations in the RPE65 gene. Those dystrophies include a form of Leber congenital amaurosis (LCA2), a rare form of retinitis pigmentosa (RP 20), and severe early childhood onset retinal dystrophy (SECORD). LCA2 is the most common of them.

Luxturna is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease, and the first adeno-associated virus (AAV) vector gene therapy approved in the US, according to Spark.

Dan Faga, Spark’s chief business officer, said the company intends to use the proceeds to continue to develop its pipeline of investigational gene therapies.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT